Welcome to our dedicated page for Sharps Technology SEC filings (Ticker: STSSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Sharps Technology’s disclosures can feel like drawing blood from a stone—hundreds of pages on syringe patents, sterilization protocols, and global manufacturing plans. Yet those details move the share price. Our platform turns that complexity into clarity.
What you’ll find here:
- Sharps Technology insider trading Form 4 transactions linked to executive stock activity
- Sharps Technology quarterly earnings report 10-Q filing with AI commentary on production costs
- Sharps Technology Form 4 insider transactions real-time alerts—no EDGAR digging required
- Sharps Technology SEC filings explained simply through AI-powered plain-language summaries
- Sharps Technology earnings report filing analysis that highlights syringe demand trends
- understanding Sharps Technology SEC documents with AI for faster due diligence
- Sharps Technology executive stock transactions Form 4 pattern recognition tools
- Sharps Technology annual report 10-K simplified—patents, plant capacity, risk factors
- Sharps Technology proxy statement executive compensation unpacked line by line
- Sharps Technology 8-K material events explained within minutes of posting
Our AI scans every newly posted 10-K, 10-Q, 8-K or S-1 and delivers real-time highlights: which SecureGard units shipped, how Hungarian output ramped, and whether management granted itself fresh options. Form 4 alerts surface insider moves before markets react, while keyword search points you straight to waste-reduction metrics buried deep in the footnotes. Want to compare quarter-over-quarter syringe margins? It’s pre-calculated. Need the exact wording on re-use prevention standards? One click opens the section in context.
Stop wading through technical jargon. Stock Titan’s AI-powered summaries, expert annotations, and real-time updates make Sharps Technology filings actionable, letting you focus on decisions—not document hunts.
Altium Capital Management LLC, Altium Healthcare Long Short Onshore Fund LP and Altium Healthcare Long Short GP LLC jointly report beneficial ownership of 35,659 shares of Sharps Technology Inc. common stock issuable upon conversion of Series A warrants, representing 3.48% of the class based on 1,023,214 shares outstanding.
The filing notes the Series A warrants are subject to a 9.99% Warrant Blocker that prevents exercise to the extent it would raise ownership above that threshold. The cover-page figures include the full number of shares issuable on conversion and do not give effect to the Warrant Blocker, so the actual number of shares the reporting persons could beneficially own after giving effect to the blocker is less than the reported amount. Reported sole voting and dispositive power are 0, with 35,659 shared voting and dispositive power.
Sharps Technology, Inc. reported its first product revenue in the quarter of $222,722 and recorded a gross loss of $1,032,027 primarily driven by cost of goods and an inventory reserve. Total assets rose to $17,085,197 and cash increased to $8,322,192, reflecting net proceeds of approximately $18.2 million from a January 2025 equity offering and partial repayment of debt.
For the six months ended June 30, 2025 the company reported net income of $5,488,141, largely attributable to a noncash fair‑value gain on warrants of $11,087,700; warrant liabilities were $1,312,848 at period end. Management discloses substantial doubt about going concern and expects to seek additional financing. The filing also discloses legal claims including a lawsuit alleging up to $1.762 million and an arbitration claim of $500,000, plus equipment purchase commitments of approximately $4.7 million.
FAQ
What is the current stock price of Sharps Technology (STSSW)?
